4-6 March 2025
Congress Center BaselBasel, Switzerland Mike KhanCEO at Argonaute RNASpeaker
Profile
Mike has taken siRNA drugs through IND to design and completion of Phase 2. He has over 25 years of experience as a leader in R&D, spanning the full spectrum of preclinical, translational and clinical development. He is a senior clinician leading one of the foremost cardio metabolic clinics in the UK. He is an expert advisor to NICE and the EC, is a member of the UK task force for Lp(a) and has contributed to establishing the current state of the art for treatment and prevention of cardiovascular diseases in the UK.
Agenda Sessions
Demonstrating a Bispecific siRNA to Reduce Cardiovascular Risk
, 14:10View Session